1-10 of 10
Aliza Rozenberg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58

Rena Pollack, Itamar Raz, Stephen D. Wiviott, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Ofri Mosenzon, Anna Maria Langkilde, Ingrid A.M. Gause-Nilsson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Marc S. Sabatine, Avivit Cahn
Journal: Diabetes Care
Diabetes Care 2023;46(1):156–164
https://doi.org/10.2337/dc22-1318
Published: 18 November 2022
View article titled, Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58
Open the PDF for Efficacy and Safety of Dapagliflozin by Baseline Insulin Regimen and Dose: Post Hoc Analyses From DECLARE-TIMI 58 in another window
Journal Articles

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial

Ofri Mosenzon, Itamar Raz, Stephen D. Wiviott, Meir Schechter, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Sabina A. Murphy, Thomas A. Zelniker, Anna Maria Langkilde, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, John P.H. Wilding, Darren K. McGuire, Deepak L. Bhatt, Lawrence A. Leiter, Avivit Cahn, Jamie P. Dwyer, Hiddo J.L. Heerspink, Marc S. Sabatine
Journal: Diabetes Care
Diabetes Care 2022;45(10):2350–2359
https://doi.org/10.2337/dc22-0382
Published: 23 August 2022
View article titled, Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
Open the PDF for Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial in another window
Journal Articles

Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58

Avivit Cahn, Stephen D. Wiviott, Ofri Mosenzon, Erica L. Goodrich, Sabina A. Murphy, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2022;45(4):938–946
https://doi.org/10.2337/dc21-1744
Published: 11 January 2022
View article titled, Association of Baseline HbA<sub>1c</sub> With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58
Open the PDF for Association of Baseline HbA<sub>1c</sub> With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58 in another window
Journal Articles

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58

Ofri Mosenzon, Stephen D. Wiviott, Hiddo J.L. Heerspink, Jamie P. Dwyer, Avivit Cahn, Erica L. Goodrich, Aliza Rozenberg, Meir Schechter, Ilan Yanuv, Sabina A. Murphy, Thomas A. Zelniker, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Martin Fredriksson, Peter A. Johansson, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Marc S. Sabatine, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2021;44(8):1805–1815
https://doi.org/10.2337/dc21-0076
Published: 11 August 2021
View article titled, The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
Open the PDF for The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58 in another window
Journal Articles

Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58

Avivit Cahn, Itamar Raz, Lawrence A. Leiter, Ofri Mosenzon, Sabina A. Murphy, Erica L. Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L. Bhatt, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Anna Maria Langkilde, Marc S. Sabatine, Stephen D. Wiviott
Journal: Diabetes Care
Diabetes Care 2021;44(5):1159–1167
https://doi.org/10.2337/dc20-2492
Published: 02 March 2021
View article titled, Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58
Open the PDF for Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58 in another window
Journal Articles

Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study

Avivit Cahn, Ofri Mosenzon, Stephen D. Wiviott, Aliza Rozenberg, Ilan Yanuv, Erica L. Goodrich, Sabina A. Murphy, Deepak L. Bhatt, Lawrence A. Leiter, Darren K. McGuire, John P.H. Wilding, Ingrid A.M. Gause-Nilsson, Martin Fredriksson, Peter A. Johansson, Anna Maria Langkilde, Marc S. Sabatine, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2020;43(2):468–475
https://doi.org/10.2337/dc19-1476
Published: 16 December 2019
View article titled, Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study
Open the PDF for Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE–TIMI 58 Study in another window
Includes: Supplementary data
Journal Articles

Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes

Marianna Yaron, Eytan Roitman, Genya Aharon-Hananel, Zohar Landau, Tali Ganz, Ilan Yanuv, Aliza Rozenberg, Moshe Karp, Maya Ish-Shalom, Joelle Singer, Julio Wainstein, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2019;42(7):1178–1184
https://doi.org/10.2337/dc18-0166
Published: 29 April 2019
View article titled, Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes
Open the PDF for Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes in another window
Includes: Supplementary data
Journal Articles

Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial

Ofri Mosenzon, Gil Leibowitz, Deepak L. Bhatt, Avivit Cahn, Boaz Hirshberg, Cheryl Wei, KyungAh Im, Aliza Rozenberg, Ilan Yanuv, Christina Stahre, Kausik K. Ray, Nayyar Iqbal, Eugene Braunwald, Benjamin M. Scirica, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2017;40(1):69–76
https://doi.org/10.2337/dc16-0621
Published: 17 October 2016
View article titled, Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial
Open the PDF for Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial in another window
Includes: Supplementary data
Journal Articles

Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial

Avivit Cahn, Itamar Raz, Ofri Mosenzon, Gil Leibowitz, Ilan Yanuv, Aliza Rozenberg, Nayyar Iqbal, Boaz Hirshberg, Mikaela Sjostrand, Christina Stahre, KyungAh Im, Estella Kanevsky, Benjamin M. Scirica, Deepak L. Bhatt, Eugene Braunwald
Journal: Diabetes Care
Diabetes Care 2016;39(8):1329–1337
https://doi.org/10.2337/dc15-2763
Published: 23 May 2016
View article titled, Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial
Open the PDF for Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial in another window
Includes: Supplementary data
Journal Articles

Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial

Ofri Mosenzon, Cheryl Wei, Jaime Davidson, Benjamin M. Scirica, Ilan Yanuv, Aliza Rozenberg, Boaz Hirshberg, Avivit Cahn, Christina Stahre, Krzysztof Strojek, Deepak L. Bhatt, Itamar Raz
Journal: Diabetes Care
Diabetes Care 2015;38(11):2142–2150
https://doi.org/10.2337/dc15-1068
Published: 10 September 2015
View article titled, Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial
Open the PDF for Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial in another window